Dr Reddy's in the news

  • Grab the opportunity when it comes

    It is time for beneficiaries of liberalization to lead

    Click Here for the Complete Story [PDF Format]
  • Dr. Reddy's prescription to stay ahead of the generic pack

    The company has differentiated itself by focusing on internal processes and staying away from costly acquisitions. Now, it has other plans to fend off the competition.

    Click Here for the Complete Story [PDF Format]
  • A new prescription

    Tectonic changes in the US generic drugs market is causing huge shifts in Indian pharma’s strategies as well.

    Click Here for the Complete Story [PDF Format]
  • Influence is a leadership tool

    Leaders can garner respect from others and achieve set targets by effectively influencing colleagues (by Saumen Chakraborty - President and Global Chief of Quality, HR& IT at Dr. Reddy’s Laboratories Ltd).

    Click Here for the Complete Story [PDF Format]
  • Affordable innovative drugs still our priority

    For Satish Reddy, joining Dr Reddy's Labs (DRL) was not a planned move, and certainly not for which he was being groomed formally.

    Click Here for the Complete Story [PDF Format]
  • India’s Dr. Reddy’s gets US nod for osteoporosis drug

    Indian drugmaker Dr Reddy's Laboratories has received U.S. Food and Drug Administration's approval for selling ibandronate sodium tablets used to treat osteoporosis, the regulator's website showed on Thursday.

    Click Here for the Complete Story [PDF Format]
  • Dr. Reddy’s lines up strong drug pipeline

    Pharmaceuticals major Dr. Reddy’s Laboratories sees a busy year ahead as it plans to launch 15-16 products in the US market, which is likely to contribute one-third to its revenues.

    Click Here for the Complete Story [PDF Format]
  • Dr. Reddy’s chalks out plan to improve India performance

    India's second largest pharmaceutical company, dr. Reddy's Laboratories, is on the verge of giving final touches to a comprehensive strategy to boost the much needed growth in the Indian market

    Click Here for the Complete Story [PDF Format]
  • Dr. Reddy's to replace DLF in Sensex

    The Bombay Stock Exchange (BSE) said today that pharma major Dr Reddy's Laboratories will replace DLF in the benchmark 30-share Sensex.

    Click Here for the Complete Story [PDF Format]
  • SMT is an empowered Multi-skilled and energetic team

    Developing an internal talent pool is important for organizations as it represents significant savings in terms of costs and on boarding time.

    Click Here for the Complete Story [PDF Format]
  • Dr Reddy's plans multi-pronged strategy to build Russian business

    Dr. Reddy's appears set for a significant scale-up in Russia, including plans for a joint venture manufacturing facility, a prescription and OTx (prescription plus switch over-the-counter) thrust and a new in-licensing pact with Novartis deepening its eng

    Click Here for the Complete Story [PDF Format]
  • Dr Reddy's: May Change Hedging Policy If Dollar Rises Sharply

    Dr. Reddy's Laboratories Ltd. may consider revising its hedging policy if the U.S. dollar gains sharply above the upper end of the Indian generic drug maker's expectations, its chief financial officer said.

    Click Here for the Complete Story [PDF Format]
  • In Good Health

    Anji Reddy may be unwell. But with a succession plan in place, no one is worried about the future of the company he founded

    Click Here for the Complete Story [PDF Format]
  • Career Journal: Hey Boss! Don't Assume Your Top Performers Are Happy

    Can good performance be taken as a parameter to judge an employee’s happiness? Not really, says Saumen Chakraborty, president and global chief of human resources, quality and information technology at Dr. Reddy’s Laboratories Ltd.

    Click Here for the Complete Story [PDF Format]
  • Stage set for easy money

    We are returning to a phase of more predictability, and things have improved on the inflation front.

    Click Here for the Complete Story [PDF Format]
  • Dr. Reddy's eyes biosimilars expansion and rejigs research focus

    Dr. Reddy's is in talks with potential partners to push into regulated markets in the biosimilars segment.

    Click Here for the Complete Story [PDF Format]